A first-in-human study of MIL95, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors and lymphomas

被引：0
|
作者：
Zhang, Qingyuan
Liu, Aiguo
Shi, Jianhua
Cai, Qingqing
Qu, Zerui
Liu, Sijun
Song, Yuqin
机构：
[1] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[2] Anhui Jimin Canc Hosp, Hefei, Peoples R China
[3] Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[5] Beijing Mabworks Biotech Co Ltd, Beijing, Peoples R China
[6] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14513
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FIRST-IN-HUMAN PHASE I TRIAL OF IBI188, AN ANTI-CD47 TARGETING MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS
    Lakhani, Nehal
    Orloff, Marlana
    Fu, Siqing
    Liu, Ying
    Wang, Yan
    Zhou, Hui
    Lin, Kedan
    Liu, Fang
    Yan, Shuling
    Patnaik, Amita
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A180 - A180
  • [2] A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.
    Burris, Howard A., III
    Spira, Alexander I.
    Taylor, Matthew H.
    Yeku, Oladapo O.
    Liu, Joyce F.
    Munster, Pamela N.
    Hamilton, Erika P.
    Thomas, Jacob Stephen
    Gatlin, Frances
    Penson, Richard T.
    Abrams, Thomas Adam
    Dhawan, Mallika Sachdev
    Walling, Jacqueline M.
    Frye, John W.
    Romanko, Kevin
    Sung, Victoria
    Brachmann, Carrie
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
    Sikic, Branimir I.
    Lakhani, Nehal J.
    Patnaik, Amita
    Shah, Sumit
    Chandana, Sreenivasa R.
    Rasco, Drew W.
    Colevas, A. Dimitrios
    O'Rourke, Timothy J.
    Papadopoulos, Kyriakos P.
    Fisher, George A.
    Chao, Mark
    Agoram, Balaji
    Chen, James Y.
    Huang, Jenny
    Axt, Matthew
    Majeti, Ravindra
    Weissman, Irving L.
    Takimoto, Chris H. M.
    Pegram, Mark D.
    Padda, Sukhmani Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors
    Lim, H. Y.
    Ahn, J. S.
    Park, J. O.
    Hong, J. Yong
    Seon, H.
    Lee, J. K.
    Lee, S. Y.
    Kim, H. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S629 - S629
  • [5] Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.
    Gan, Hui Kong
    Coward, Jermaine
    Mislang, Anna Rachelle Austria
    Cosman, Rasha
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Dennis
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
    Johanna Bendell
    Patricia LoRusso
    Michael Overman
    Anne M. Noonan
    Dong-Wan Kim
    John H. Strickler
    Sang-We Kim
    Stephen Clarke
    Thomas J. George
    Peter S. Grimison
    Minal Barve
    Manik Amin
    Jayesh Desai
    Trisha Wise-Draper
    Steven Eck
    Yu Jiang
    Anis A. Khan
    Yuling Wu
    Philip Martin
    Zachary A. Cooper
    Nairouz Elgeioushi
    Nancy Mueller
    Rakesh Kumar
    Sandip Pravin Patel
    Cancer Immunology, Immunotherapy, 2023, 72 : 2443 - 2458
  • [7] First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
    Bendell, Johanna
    LoRusso, Patricia
    Overman, Michael
    Noonan, Anne M.
    Kim, Dong-Wan
    Strickler, John H.
    Kim, Sang-We
    Clarke, Stephen
    George, Thomas J.
    Grimison, Peter S.
    Barve, Minal
    Amin, Manik
    Desai, Jayesh
    Wise-Draper, Trisha
    Eck, Steven
    Jiang, Yu
    Khan, Anis A.
    Wu, Yuling
    Martin, Philip
    Cooper, Zachary A.
    Elgeioushi, Nairouz
    Mueller, Nancy
    Kumar, Rakesh
    Patel, Sandip Pravin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2443 - 2458
  • [8] A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
    Beaufils, M.
    Mailliez, A.
    Sfumato, P.
    Vicier, C.
    Gross, M. Provansal
    Guerin, M.
    Chanez, B.
    Kotecki, N.
    Widemann, A.
    Panzolato, S.
    Chammard, A. Boyer
    Andre, P.
    Paturel, C. L.
    Gouarne, C.
    Awada, A. H.
    Boher, J. M.
    Goncalves, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S682 - S683
  • [9] A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors
    Naing, A.
    Goel, S.
    Curti, B.
    Weise, A.
    Eder, J. P.
    Marshall, S.
    Morehouse, C.
    Li, X.
    Karakunnel, J. J.
    Infante, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] A PHASE 1 STUDY TO EVALUATE THE SAFETY, PK, AND ANTITUMOR ACTIVITY OF AK117, AN ANTI-CD47 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY ADVANCED OR METASTATIC SOLID TUMORS OR LYMPHOMAS
    Prawira, Amy
    Coward, Jermaine
    Mislang, Anna
    Nagrial, Adnan
    Gan, Hui
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Dennis
    Xia, Yu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A233 - A233
12345